IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation.
Saved in:
| Title: | IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. |
|---|---|
| Authors: | Hack SP; Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA., Spahn J; Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA., Chen M; Department of Hepatobiliary Surgery, Cancer Centre of Sun Yat-sen University, Guangzhou, PR China., Cheng AL; National Taiwan University Cancer Center & National Taiwan University Hospital, Taipei, Taiwan., Kaseb A; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Kudo M; Department of Gastroenterology & Hepatology, Kindai University School of Medicine, Osaka, Japan., Lee HC; Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Yopp A; Department of Surgery, Division of Surgical Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA., Chow P; Division of Surgical Oncology, National Cancer Centre, Singapore., Qin S; PLA Cancer Center, People's Liberation Army (PLA) 81 Hospital, Nanjing 210016, PR China. |
| Source: | Future oncology (London, England) [Future Oncol] 2020 May; Vol. 16 (15), pp. 975-989. Date of Electronic Publication: 2020 Apr 30. |
| Publication Type: | Clinical Trial Protocol; Journal Article |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 32352320 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Hack+SP%22">Hack SP</searchLink>; Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA.<br /><searchLink fieldCode="AU" term="%22Spahn+J%22">Spahn J</searchLink>; Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA.<br /><searchLink fieldCode="AU" term="%22Chen+M%22">Chen M</searchLink>; Department of Hepatobiliary Surgery, Cancer Centre of Sun Yat-sen University, Guangzhou, PR China.<br /><searchLink fieldCode="AU" term="%22Cheng+AL%22">Cheng AL</searchLink>; National Taiwan University Cancer Center & National Taiwan University Hospital, Taipei, Taiwan.<br /><searchLink fieldCode="AU" term="%22Kaseb+A%22">Kaseb A</searchLink>; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.<br /><searchLink fieldCode="AU" term="%22Kudo+M%22">Kudo M</searchLink>; Department of Gastroenterology & Hepatology, Kindai University School of Medicine, Osaka, Japan.<br /><searchLink fieldCode="AU" term="%22Lee+HC%22">Lee HC</searchLink>; Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Yopp+A%22">Yopp A</searchLink>; Department of Surgery, Division of Surgical Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.<br /><searchLink fieldCode="AU" term="%22Chow+P%22">Chow P</searchLink>; Division of Surgical Oncology, National Cancer Centre, Singapore.<br /><searchLink fieldCode="AU" term="%22Qin+S%22">Qin S</searchLink>; PLA Cancer Center, People's Liberation Army (PLA) 81 Hospital, Nanjing 210016, PR China. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101256629%22">Future oncology (London, England)</searchLink> [Future Oncol] 2020 May; Vol. 16 (15), pp. 975-989. <i>Date of Electronic Publication: </i>2020 Apr 30. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial Protocol; Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101256629 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1744-8301 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214796694%22">14796694 </searchLink><i>NLM ISO Abbreviation: </i>Future Oncol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=32352320 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.2217/fon-2020-0162 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 975 Titles: – TitleFull: IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Hack SP – PersonEntity: Name: NameFull: Spahn J – PersonEntity: Name: NameFull: Chen M – PersonEntity: Name: NameFull: Cheng AL – PersonEntity: Name: NameFull: Kaseb A – PersonEntity: Name: NameFull: Kudo M – PersonEntity: Name: NameFull: Lee HC – PersonEntity: Name: NameFull: Yopp A – PersonEntity: Name: NameFull: Chow P – PersonEntity: Name: NameFull: Qin S IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 05 Text: 2020 May Type: published Y: 2020 Identifiers: – Type: issn-electronic Value: 1744-8301 Numbering: – Type: volume Value: 16 – Type: issue Value: 15 Titles: – TitleFull: Future oncology (London, England) Type: main |
| ResultId | 1 |
